Related to MSC-Secreted Factor Key to Impact of Multiple Sclerosis Cell Therapy

• EU Approves Biogen Idec’s Avonex Intramuscular Autoinjector Product for MS
  
• U.S. Army Institute of Surgical Research Taps Arteriocyte for Orthopedic Trauma Cellular Therapies
  
• Merck Serono Gives Up on Getting Drug Candidate for Multiple Sclerosis Approved
  
• Digna and Flamel Partner on Drug Delivery Formulations for Multiple Candidates
  
• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• Nanostructured Support Developed for Maintaining MSCs in Undifferentiated, Multipotent State
  
• EC Conditionally Approves Biogen Idec’s Multiple Sclerosis Drug Fampyra
  
• Merck Serono Acquires Phase II-Ready Multiple Sclerosis Candidate Originally Developed by Peptimmune
  
• Cardio3 Establishes U.S. Subsidiary in Advance of Phase III Heart Failure Cell Therapy Trial
  
• Japan Approves Novartis’ MS Drug Gilenya and CAPS Treatment Ilaris
  
• Cellerix Secures €4.95M for Phase III Study of Allogeneic Adult Stem Cell Therapy
  
• Merck Serono and Ono Sign Separate Agreements Worth $25M for MS and Cancer Drugs
  
• Sanofi and Genzyme Report Positive New Data from Phase III Multiple Sclerosis Study
  
• Positive Results Reported for Biogen Idec’s Oral MS Drug in First Phase III Study
  
• Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug
  
• Biogen Idec Reports Positive Data from Second Phase III Trial with Multiple Sclerosis Drug
  
• Dedifferentiating Neuronal Progenitors to Stem-Like State Increases Survival In Vivo and Boosts Therapeutic Effects
  
• FDA Sanctions NYBC’s Cord Blood Hematopoietic Progenitor Cells for Transplantation
  
• Genzyme’s mAb for Multiple Sclerosis Succeeds in Second Phase III Trial
  
• First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results